Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
J Atten Disord. 2004 Oct; 8(2):45-52.JA

Abstract

OBJECTIVE

To compare the safety and efficacy of atomoxetine, a selective inhibitor of the norepinephrine transporter, versus placebo in Attention-Deficit/Hyperactivity Disorder (ADHD) patients with comorbid Oppositional Defiant Disorder (ODD).

METHODS

A subset analysis of 98 children from two identical, multi-site, double-blind, randomized, placebo-controlled trials involving 9 weeks of treatment with atomoxetine or placebo was conducted. Patients met DSM-IV ADHD criteria. ODD was diagnosed with the Diagnostic Interview for Children and Adolescents-IV (DICA-IV; Reich, Weiner, and Herjanic, 1997). ADHD severity was assessed with the ADHD Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHD-RS-IV-Parent:lnv; DuPaul, Power, Anastopoulos, and Reid, 1998); the short version of the Conners' Parent Rating Scales-Revised (CPRS-R:S; Conners, 2000); and the Clinical Global Impressions of ADHD Severity (CGI-ADHD-S; Guy, 1976). Clinical response was defined as a > or = 25% reduction in ADHD-RS-IV-Parent:lnv total score.

RESULTS

ADHD-RS-IV-Parent:lnv, CGI-ADHD-S, and three CPRS-R:S subscale scores improved markedly with atomoxetine treatment. However, a decrease in the CPRS-R:S Oppositional subscore for atomoxetine-treated patients was not significantly greater than scores for placebo-treated patients. Clinical response rates were 65.4% in the atomoxetine group, and 36.4% in the placebo group (p = .007).

CONCLUSION

Atomoxetine was effective for the treatment of ADHD in patients with comorbid ODD. It did not significantly reduce the severity of ODD symptoms, and was well tolerated by the patients.

Authors+Show Affiliations

Penn State Hershey Medical Center, Department of Psychiatry, Hershey, PA 17033, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

15801334

Citation

Kaplan, S, et al. "Efficacy and Safety of Atomoxetine in Childhood Attention-deficit/hyperactivity Disorder With Comorbid Oppositional Defiant Disorder." Journal of Attention Disorders, vol. 8, no. 2, 2004, pp. 45-52.
Kaplan S, Heiligenstein J, West S, et al. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004;8(2):45-52.
Kaplan, S., Heiligenstein, J., West, S., Busner, J., Harder, D., Dittmann, R., Casat, C., & Wernicke, J. F. (2004). Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. Journal of Attention Disorders, 8(2), 45-52.
Kaplan S, et al. Efficacy and Safety of Atomoxetine in Childhood Attention-deficit/hyperactivity Disorder With Comorbid Oppositional Defiant Disorder. J Atten Disord. 2004;8(2):45-52. PubMed PMID: 15801334.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. AU - Kaplan,S, AU - Heiligenstein,J, AU - West,S, AU - Busner,J, AU - Harder,D, AU - Dittmann,R, AU - Casat,C, AU - Wernicke,J F, PY - 2005/4/2/pubmed PY - 2005/5/18/medline PY - 2005/4/2/entrez SP - 45 EP - 52 JF - Journal of attention disorders JO - J Atten Disord VL - 8 IS - 2 N2 - OBJECTIVE: To compare the safety and efficacy of atomoxetine, a selective inhibitor of the norepinephrine transporter, versus placebo in Attention-Deficit/Hyperactivity Disorder (ADHD) patients with comorbid Oppositional Defiant Disorder (ODD). METHODS: A subset analysis of 98 children from two identical, multi-site, double-blind, randomized, placebo-controlled trials involving 9 weeks of treatment with atomoxetine or placebo was conducted. Patients met DSM-IV ADHD criteria. ODD was diagnosed with the Diagnostic Interview for Children and Adolescents-IV (DICA-IV; Reich, Weiner, and Herjanic, 1997). ADHD severity was assessed with the ADHD Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHD-RS-IV-Parent:lnv; DuPaul, Power, Anastopoulos, and Reid, 1998); the short version of the Conners' Parent Rating Scales-Revised (CPRS-R:S; Conners, 2000); and the Clinical Global Impressions of ADHD Severity (CGI-ADHD-S; Guy, 1976). Clinical response was defined as a > or = 25% reduction in ADHD-RS-IV-Parent:lnv total score. RESULTS: ADHD-RS-IV-Parent:lnv, CGI-ADHD-S, and three CPRS-R:S subscale scores improved markedly with atomoxetine treatment. However, a decrease in the CPRS-R:S Oppositional subscore for atomoxetine-treated patients was not significantly greater than scores for placebo-treated patients. Clinical response rates were 65.4% in the atomoxetine group, and 36.4% in the placebo group (p = .007). CONCLUSION: Atomoxetine was effective for the treatment of ADHD in patients with comorbid ODD. It did not significantly reduce the severity of ODD symptoms, and was well tolerated by the patients. SN - 1087-0547 UR - https://www.unboundmedicine.com/medline/citation/15801334/Efficacy_and_safety_of_atomoxetine_in_childhood_attention_deficit/hyperactivity_disorder_with_comorbid_oppositional_defiant_disorder_ L2 - https://journals.sagepub.com/doi/10.1177/108705470400800202?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -